PhaseBio Pharmaceuticals, Inc.
METHODS OF REVERSING TICAGRELOR ACTIVITY
Last updated:
Abstract:
The present disclosure provides a method of reversing ticagrelor-associated bleeding in a patient by administering an antibody or fragment thereof that binds to ticagrelor.
Status:
Application
Type:
Utility
Filling date:
20 Sep 2019
Issue date:
11 Nov 2021